FDA announces end to Wegovy and Ozempic drug shortages

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced. On Feb. 21,
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).

FDA, Medtronic and Parkinson's

FiercePharma16h
In letter to RFK Jr., Democrats flag threats to drug review process from FDA firings
HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated letters from lawmakers outlining the threats ...
Insight: Smokescreen: some vape firms pivot after FDA crackdown
Some e-cigarette companies targeted by U.S. authorities have altered their business model or changed their corporate ...
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
FDA moves to rehire medical device, food safety and other staffers fired days earlier
The reversal is the latest example of President Donald Trump and billionaire Elon Musk’s chaotic approach to cost-cutting, ...
Frozen shakes served at nursing homes recalled after being linked to numerous deaths, hospitalizations: FDA
The FDA announced that a food distributor is recalling all ReadyCare and Sysco Imperial Frozen Supplemental shakes, typically ...
Newser on MSN12h
FDA Change on Ozempic to Shake Up the Market
The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...